Cortexin
Not FDA approvedBrain-derived polypeptide complex
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Cortexin is a mixture of low-molecular-weight polypeptides extracted from the cerebral cortex of calves or pigs, developed in Russia. It is thought to act as a neuroprotective agent, possibly by influencing neurotransmitter balance, reducing oxidative stress, and supporting nerve cell survival, though its exact mechanism is not well defined.
What the evidence shows
Cortexin is not FDA-approved and has no registered human trials in international databases; most clinical studies come from Russian and Eastern European literature and are generally small or of uneven quality. Its benefits in humans are not established by rigorous, independently replicated trials.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Multiple signaling conduits regulate global differentiation-specific gene expression in PC12 cells.
A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly.
[Cortexin. Molecular mechanisms and targets of neuroprotective activity].
Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.